Conditions for eradicating hepatitis C in people who inject drugs: a fibrosis aware model of hepatitis C virus transmission. (English) Zbl 1343.92518
Summary: It is estimated that 80% of new hepatitis C virus (HCV) infections occur among people who inject drugs (PWID). Eradicating HCV from this population is key for the complete eradication of the disease, and the advent of simple to use, high efficacy treatments could conceivably make this scenario possible. This paper presents a mathematical model where transmission of HCV is studied in a simulated population of PWID where fibrosis progression is explicitly tracked. The stability thresholds that determine whether HCV will remain endemic or become eradicated were established numerically, and analytically on a reduced version of the model. Conditions on testing and treatment rates for eradication to occur were determined, within the context of the new high efficacy therapies. The results show that HCV eradication in the PWID population of the Vancouver, BC test scenario is achievable, but testing and especially treatment rates will need to increase significantly from current rates. Parameter estimates were drawn from published data.
MSC:
| 92D30 | Epidemiology |
References:
| [1] | Alavi, M.; Raffa, J. D.; Deans, G. D.; Lai, C.; Krajden, M.; Dore, G. J., Continued low uptake of treatment for hepatitis C virus infection in a large community-based cohort of inner city residents, Liver Int., 34, 8, 1198-1206 (2013) |
| [2] | Anderson, R. M.; May, R. M., Population biology of infectious diseasespart I, Nature, 280, 5721, 361-367 (1979) |
| [3] | Bedossa, P.; Poynard, T., An algorithm for the grading of activity in chronic hepatitis C, Hepatology, 24, 2, 289-293 (1996) |
| [4] | Dalgard, O., Follow-up studies of treatment for hepatitis C virus infection among injection drug users, Clin. Infect. Dis., 40, S336-S338 (2005) |
| [5] | Diekmann, O.; Heesterbeek, J.; Roberts, M., The construction of next-generation matrices for compartmental epidemic models, J. R. Soc. Interface, 873-885 (2009) |
| [6] | Diekmann, O.; Heesterbeek, H.; Britton, T., Mathematical Tools for Understanding Infectious Disease Dynamics (2012), Princeton University Press: Princeton University Press Oxford and Princeton, NJ · Zbl 1304.92009 |
| [7] | Elbasha, E. H., Model for hepatitis C virus transmissions, Math. Biosci. Eng., 10, 4 (2013) · Zbl 1273.92053 |
| [8] | Feeney, E. R.; Chung, R. T., Antiviral treatment of hepatitis C, Br. Med. J., 349, g3308 (2014) |
| [9] | George, S. L.; Bacon, B. R.; Brunt, E. M.; Mihindukulasuriya, K. L.; Hoffmann, J.; Di Bisceglie, A. M., Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapya 5-year follow-up of 150 patients, Hepatology, 49, 3, 729-738 (2009) |
| [10] | Grebely, J.; Raffa, J. D.; Lai, C.; Krajden, M.; Kerr, T.; Fischer, B., Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents, J. Viral Hepat., 16, 5, 352-358 (2009) |
| [11] | Grebely, J.; Knight, E.; Ngai, T.; Genoway, K. A.; Raffa, J. D.; Storms, M., Reinfection with hepatitis C virus following sustained virological response in injection drug users, J. Gastroenterol. Hepatol., 25, 7, 1281-1284 (2010) |
| [12] | Grebely, J.; Matthews, G. V.; Lloyd, A. R.; Dore, G. J., Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements, Clin. Infect. Dis., 57, 7, 1014-1020 (2013) |
| [13] | Grebely, J.; Page, K.; Sacks-Davis, R.; Loeff, M. S.; Rice, T. M.; Bruneau, J., The effects of female sex, viral genotype, and il28b genotype on spontaneous clearance of acute hepatitis C virus infection, Hepatology, 59, 1, 109-120 (2014) |
| [14] | Grebely, J.; Lima, V. D.; Marshall, B. D.; Milloy, M.; DeBeck, K.; Montaner, J., Declining incidence of hepatitis C virus infection among people who inject drugs in a Canadian setting, 1996-2012, PLoS ONE, 9, 6, e97726 (2014) |
| [16] | Hézode, C.; Fontaine, H.; Dorival, C.; Larrey, D.; Zoulim, F.; Canva, V., Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890, J. Hepatol., 59, 3, 434-441 (2013) |
| [17] | Hull, M.; Klein, M.; Shafran, S.; Tseng, A.; Giguere, P.; Cote, P., CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases CoreCanadian guidelines for management and treatment of HIV/hepatitis C coinfection in adults, Can. J. Infect. Dis. Med. Microbiol. (Journal Canadien des Maladies Infectieuses et de la Microbiologie Medicale/AMMI Canada), 24, 4, 217-238 (2012) |
| [18] | Iversen, J.; Grebely, J.; Topp, L.; Wand, H.; Dore, G.; Maher, L., Uptake of hepatitis C treatment among people who inject drugs attending needle and syringe programs in Australia, 1999-2011, J. Viral Hepat., 21, 3, 198-207 (2014) |
| [19] | Jaeckel, E.; Cornberg, M.; Wedemeyer, H.; Santantonio, T.; Mayer, J.; Zankel, M., Treatment of acute hepatitis C with interferon alfa-2b, New Engl. J. Med., 345, 20, 1452-1457 (2001) |
| [21] | Keller, H. B., Lectures on Numerical Methods in Bifurcation Theory. Tata Institute of Fundamental Research Lectures on Mathematics and Physics (1987), Springer-Verlag: Springer-Verlag New York · Zbl 0656.65063 |
| [22] | Kleinman, S. H.; Lelie, N.; Busch, M. P., Infectivity of human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus and risk of transmission by transfusion, Transfusion, 49, 11, 2454-2489 (2009) |
| [23] | Kwon, J. A.; Iversen, J.; Maher, L.; Law, M. G.; Wilson, D. P., The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australiaa model-based analysis (1999), J. Acquir. Immune Defic. Syndr., 51, 4, 462-469 (2009) |
| [24] | Lavanchy, D., The global burden of hepatitis C, Liver Int., 29, s1, 74-81 (2009) |
| [25] | Lawitz, E.; Mangia, A.; Wyles, D.; Rodriguez-Torres, M.; Hassanein, T.; Gordon, S. C., Sofosbuvir for previously untreated chronic hepatitis C infection, New Engl. J. Med., 368, 20, 1878-1887 (2013) |
| [26] | Lima, V. D.; Rozada, I.; Grebely, J.; Hull, M.; Lourenco, L.; Nosyk, B., Are interferon-free direct-acting antivirals for the treatment of HCV enough to control the epidemic among people who inject drugs?, PLoS ONE, 10, 12, e0143836 (2015) |
| [27] | Ly, K. N.; Xing, J.; Klevens, R. M.; Jiles, R. B.; Ward, J. W.; Holmberg, S. D., The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007, Ann. Internal Med., 156, 4, 271-278 (2012) |
| [28] | Marcellin, P.; Gane, E.; Buti, M.; Afdhal, N.; Sievert, W.; Jacobson, I. M., Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis ba 5-year open-label follow-up study, Lancet, 381, 9865, 468-475 (2013) |
| [29] | Martin, N. K.; Vickerman, P.; Grebely, J.; Hellard, M.; Hutchinson, S. J.; Lima, V. D., Hepatitis C virus treatment for prevention among people who inject drugsmodeling treatment scale-up in the age of direct-acting antivirals, Hepatology, 58, 5, 1598-1609 (2013) |
| [30] | Micallef, J.; Kaldor, J.; Dore, G., Spontaneous viral clearance following acute hepatitis C infectiona systematic review of longitudinal studies, J. Viral Hepat., 13, 1, 34-41 (2006) |
| [31] | Mondelli, M. U.; Cerino, A.; Cividini, A., Acute hepatitis Cdiagnosis and management, J. Hepatol., 42, 1, S108-S114 (2005) |
| [32] | Nelson, P. K.; Mathers, B. M.; Cowie, B.; Hagan, H.; Des Jarlais, D.; Horyniak, D., Global epidemiology of hepatitis B and hepatitis C in people who inject drugsresults of systematic reviews, Lancet, 378, 9791, 571-583 (2011) |
| [33] | Puri, N.; DeBeck, K.; Feng, C.; Kerr, T.; Rieb, L.; Wood, E., Gender influences on hepatitis C incidence among street youth in a Canadian setting, J. Adolesc. Health, 55, 6, 830-834 (2014) |
| [34] | Razavi, H.; Waked, I.; Sarrazin, C.; Myers, R.; Idilman, R.; Calinas, F., The present and future disease burden of hepatitis C virus (HCV) infection with today׳s treatment paradigm, J. Viral Hepat., 21, s1, 34-59 (2014) |
| [37] | Shiratori, Y.; Imazeki, F.; Moriyama, M.; Yano, M.; Arakawa, Y.; Yokosuka, O., Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy, Ann. Internal Med., 132, 7, 517-524 (2000) |
| [38] | Thein, H. H.; Yi, Q.; Dore, G. J.; Krahn, M. D., Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infectiona meta-analysis and meta-regression, Hepatology, 48, 2, 418-431 (2008) |
| [39] | Turner, K. M.; Hutchinson, S.; Vickerman, P.; Hope, V.; Craine, N.; Palmateer, N., The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug userspooling of UK evidence, Addiction, 106, 11, 1978-1988 (2011) |
| [41] | Van den Driessche, P.; Watmough, J., Reproduction numbers and sub-threshold endemic equilibria for compartmental models of disease transmission, Math. Biosci., 180, 1, 29-48 (2002) · Zbl 1015.92036 |
| [42] | Yu, A.; Spinelli, J. J.; Cook, D. A.; Buxton, J. A.; Krajden, M., Mortality among British Columbians testing for hepatitis C antibody, BMC Public Health, 13, 1, 291 (2013) |
This reference list is based on information provided by the publisher or from digital mathematics libraries. Its items are heuristically matched to zbMATH identifiers and may contain data conversion errors. In some cases that data have been complemented/enhanced by data from zbMATH Open. This attempts to reflect the references listed in the original paper as accurately as possible without claiming completeness or a perfect matching.
